- Oncotelic’s PDAOAI platform indexes 125,000+ PubMed abstracts on TGF-β signaling, enabling researchers to interrogate the evidence for testable, auditable hypotheses rather than rely on black-box predictions.
- Recent industry coverage places Oncotelic alongside Rockwell Automation, Emerson Electric, Thermo Fisher Scientific, and Danaher as contributors to the pharmaceutical sector’s shift toward AI-integrated operations.
- The hypothesis-first approach addresses a core challenge in biotech research: reducing training-set bias and building transparent, reproducible chains from question to evidence to hypothesis.
Pharmaceutical research and manufacturing are undergoing a structural transition. Regulatory agencies are raising expectations around data integrity and traceability, while the industry is shifting from retrospective audits toward continuous, AI-enabled monitoring systems. At the same time, drug discovery is being reshaped by the growing availability of large-scale biomedical data and the tools to interrogate it at scale. Both shifts reflect a common underlying reality: manual processes and isolated datasets are no longer sufficient in an environment where scientific literature expands rapidly and regulatory expectations demand continuous, defensible documentation. Oncotelic Therapeutics (OTCQB: OTLC) has responded to this environment with PDAOAI, an evidence-interrogation platform designed to surface testable research hypotheses from the global TGF-β literature.
What PDAOAI Does Differently
Instead of relying on traditional predictive models trained to replicate historical datasets, PDAOAI takes a retrieval-and-interrogation approach. The platform organizes and connects large volumes of biomedical literature, enabling researchers to identify patterns and generate testable hypotheses with direct links to underlying source data.
Each output is tied back to its originating evidence, creating an auditable chain from question to evidence to hypothesis. This distinction is increasingly relevant as concerns grow around model transparency, reproducibility, and training-set bias in biomedical AI. By positioning itself as an interrogation layer rather than a black-box predictor, Oncotelic is aligning its platform with the practical requirements of research environments where every conclusion must be validated and defensible.
The TGF-β Corpus
The platform’s initial deployment focuses on a corpus of more than 125,000 PubMed abstracts centered on transforming growth factor beta (“TGF-β”), a signaling pathway implicated in cancer progression, immune response, fibrosis, and metabolic disease. TGF-β is also the scientific foundation of Oncotelic’s lead therapeutic candidate, OT-101, a first-in-class anti-TGF-β RNA-based therapy.
By structuring and analyzing this body of literature, PDAOAI allows researchers to move beyond keyword searches to explore relationships across datasets, identifying recurring biological patterns and potential mechanistic links that may inform future development strategies.
A Broader Industry Transition
The context for Oncotelic’s platform extends beyond drug discovery. A recent editorial positioned the company within a broader group of organizations contributing to the integration of artificial intelligence across pharmaceutical and life sciences operations. This group includes Rockwell Automation Inc., Emerson Electric Co., Thermo Fisher Scientific Inc., and Danaher Corp., each advancing AI-enabled systems across industrial and laboratory environments.
Parallel developments are taking place in manufacturing. Nightfood Holdings Inc., operating as TechForce Robotics, has advanced AI-enabled robotic systems designed to automate sterile manufacturing environments, reinforcing the industry’s shift toward integrated, real-time compliance systems.
Together, these developments reflect a wider transition toward interconnected, intelligent systems across the pharmaceutical value chain, spanning both research and production.
Why the Positioning Matters
Regulatory frameworks such as the European Union’s updated GMP Annex 1 and initiatives from the U.S. Food and Drug Administration are encouraging the adoption of continuous monitoring, embedded intelligence, and automated documentation. These changes are contributing to what is increasingly described as Pharma 4.0, an environment where data flows continuously across systems and compliance is integrated into every stage of the process.
While PDAOAI operates at the discovery and hypothesis-generation stage rather than in manufacturing, the underlying principle is consistent: replacing fragmented, manual processes with systems that are continuously auditable, reproducible, and resistant to bias.
For Oncotelic, this positioning connects its therapeutic pipeline, including OT-101 and its focus on rare and underserved indications, to a broader infrastructure shift occurring across the industry.
Closing Perspective
As artificial intelligence continues to expand across both discovery and manufacturing environments, platforms that enable traceable, reproducible, and evidence-based decision-making are becoming central to pharmaceutical development.
Within this evolving framework, PDAOAI reflects a model focused not on prediction alone, but on structured interrogation of the underlying evidence – a distinction that may become more important as the industry places greater emphasis on transparency, validation, and data integrity.
For more information, visit the company’s website at www.Oncotelic.com.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC
